Spire Healthcare Group (LON:SPI) Hits New 52-Week High After Analyst Upgrade

Spire Healthcare Group plc (LON:SPI - Get Free Report) reached a new 52-week high during trading on Thursday after Berenberg Bank raised their price target on the stock from GBX 286 to GBX 300. Berenberg Bank currently has a buy rating on the stock. Spire Healthcare Group traded as high as GBX 252.50 ($3.14) and last traded at GBX 248 ($3.09), with a volume of 3522562 shares changing hands. The stock had previously closed at GBX 238.50 ($2.97).

Separately, JPMorgan Chase & Co. reissued an "overweight" rating and set a GBX 295 ($3.67) price target on shares of Spire Healthcare Group in a research report on Monday, February 26th.

Spire Healthcare Group Price Performance

The company has a current ratio of 0.69, a quick ratio of 0.74 and a debt-to-equity ratio of 170.37. The firm has a market capitalization of £1.00 billion, a PE ratio of 3,514.29, a P/E/G ratio of 1.06 and a beta of 0.99. The firm's fifty day moving average price is GBX 237.41 and its 200 day moving average price is GBX 228.84.

Spire Healthcare Group Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, June 21st. Stockholders of record on Thursday, May 23rd will be issued a GBX 2.10 ($0.03) dividend. This represents a dividend yield of 0.89%. The ex-dividend date is Thursday, May 23rd. This is a boost from Spire Healthcare Group's previous dividend of $0.50. Spire Healthcare Group's payout ratio is 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.